Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the ...

British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...

The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...

U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...